A Study of SHR-4610 Injection in Patients With Advanced Solid Tumors

Inclusion criteria

• Subjects must voluntarily agree to participate in the trial and sign a written informed consent form;
• Age range: 18-75 years old, both male and female are welcome;
• Patients with histologically or cytologically confirmed unresectable locally advanced or metastatic solid tumors which is relapsed or refractory to standard treatment, or lack of standard treatment;
• Have at least one measurable tumor lesion per RECIST v1.1;
• ECOG performance status of 0-1;
• Life expectancy ≥ 12 weeks;
• Adequate bone marrow and organ function.

Exclusion criteria

• Patients with active central nervous system metastases or meningeal metastases;
• Systemic antitumor therapy was received 4 weeks before the start of the study;
• Moderate or severe ascites with clinical symptoms; Uncontrolled or moderate or higher pleural effusion or pericardial effusion;
• Have poorly controlled or severe cardiovascular disease;
• Subjects with active hepatitis B or active hepatitis C;
• Adverse reactions of previous anti-tumor treatment have not recovered to Grade ≤ 1 per NCI-CTCAE v5.0.